Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Ashish C. Bhatia MD, FAAD Associate Editor

Robert T. Brodell MD, FAAD Editor-in-Chief

See All Experts

featured

Published in Dermatology

Journal Scan / Research · July 02, 2015

Secukinumab Superior to Ustekinumab for Moderate to Severe Plaque Psoriasis

Journal of the American Academy of Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Robert Brodell MD, FAAD

Journal of the American Academy of Dermatology

Secukinumab Is Superior to Ustekinumab in Clearing Skin of Subjects With Moderate to Severe Plaque Psoriasis: CLEAR, a Randomized Controlled Trial

J Am Acad Dermatol 2015 Jun 16;[EPub Ahead of Print], D Thaçi, A Blauvelt, K Reich, TF Tsai, F Vanaclocha, K Kingo, M Ziv, A Pinter, S Hugot, R You, M Milutinovic

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Secukinumab Superior to Ustekinumab for Moderate to Severe Plaque Psoriasis

Additional Info

Secukinumab Is Superior to Ustekinumab in Clearing Skin of Subjects With Moderate to Severe Plaque Psoriasis: CLEAR, a Randomized Controlled Trial

Further Reading

Evaluation and Surgical Management of Pediatric Cutaneous Melanoma, Atypical Spitz Tumors, and Non-Spitz Melanocytic Tumors

Safety of Biologic Use During Pregnancy and Breastfeeding in Dermatology

Impact of Clinical Information on Melanocytic Skin Lesion Pathology Diagnosis

Local Recurrence, Metastasis, and Mortality Rates Among Patients With Thin and In Situ Melanomas

Suicidal and Self-Injurious Behaviors Among Patients With Psoriasis or Psoriatic Arthritis Treated With Biologics

Association Between Treatment With Biologics and Cardiovascular Comorbidities in Patients With Psoriasis

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Efficacy of Treatment With Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis Through 76 Weeks

Non-SCORTEN Predictors of Mortality Among Patients With SJS/TEN

Risk Factors for Subclinical Spread in Patients With Melanoma In Situ and Invasive Melanoma

Outcomes of Dermoscopic vs Naked-Eye Evaluation of Surgical Margins in Patients With Nonmelanoma Skin Cancer Undergoing Mohs Micrographic Surgery

Recently Updated